News & Events

October 29, 2020 - AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

• Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH)
• WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch

Press release: English

_______________________________________________________________________________________________________________

March 3, 2020 - AB2 Bio appoints Michael Soldan CEO, an experienced industry executive to prepare market entry of lead product, Tadekinig alfa to treat HLH and other rare, orphan diseases.

Press release: English

_______________________________________________________________________________________________________________

March 21, 2019 - AB2 Bio announces readiness for recruitment in pivotal Phase 3 trial of Tadekinig alfa, a novel human recombinant interleukin-18 binding protein, in children with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency, with amended design in the U.S. and Canada.

Press release: English

_______________________________________________________________________________________________________________

April 3, 2017 - AB2 Bio Ltd’s Tadekinig alfa therapy receives Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of monogenic, Interleukin-18 (IL-18) associated autoinflammatory conditions with ongoing systemic inflammation. In addition, AB2 Bio Ltd receives Orphan Drug Designation from the FDA for the treatment of Haemophagocytic Lymphohistiocytosis (HLH).

• Breakthrough Therapy Designation (BTD) recognises the major potential therapeutic benefits of Tadekinig alfa (IL-18BP) in the treatment of severe and potentially fatal autoinflammatory conditions
• FDA BTD and ODD status supports the accelerated development of Tadekinig alfa

Press release: English / Français / Deutsch

_______________________________________________________________________________________________________________

November 29, 2016 - AB2 Bio Ltd receives Orphan Drug Designation from the European Medicines Agency for the treatment of Haemophagocytic Lymphohistiocytosis (HLH)

• Important regulatory milestone recognizing the potential therapeutic benefits of IL-18BP in treating HLH, a broad family of severe autoinflammatory diseases with high unmet medical need
• EMA ODD status supports accelerated Phase III development of Tadekinig alfa (IL-18BP)

Press release: English / Français / Deutsch

_______________________________________________________________________________________________________________

January 11, 2016 - AB2 Bio Ltd raises CHF 21 million (USD 21 million) in Series B financing round

• Over CHF 41 million raised since the foundation of the company
• Strong commitment from current and new investors
• Company funded through Phase II trial in Adult onset Still’s disease and a pivotal Phase III trial in a rare genetic disease

Press release: English / Français / Deutsch

_______________________________________________________________________________________________________________

November 9, 2015 - AB2 Bio Ltd achieves a medical breakthrough in the treatment of systemic inflammation

• Drug candidate effective in treating a baby girl carrying a newly identified, potentially fatal, genetic mutation causing severe systemic inflammation
• Case report to be presented at the Annual Meeting of the American College of Rheumatology (ACR)

Press release: English / Français / Deutsch

_______________________________________________________________________________________________________________
Investor & Media Relations:
Marieke Vermeersch
LifeSci Advisors
Phone: +32 479 490 603
mvermeersch@lifesciadvisors.com